+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Dermatologicals in Poland

  • PDF Icon

    Report

  • 25 Pages
  • October 2024
  • Region: Poland
  • Euromonitor International
  • ID: 2651912
Dermatologicals in Poland are expected to register minimal constant value growth in 2024, with volume sales also falling across many product areas. Topical antifungals, as well as nappy (diaper) rash treatments, continue to account for most value sales, but cold sore treatments, as well as hair loss treatments are expected to register the highest volume growth in 2024. Hair loss treatments is an emerging sector, with plenty of room for further growth.

The Dermatologicals in Poland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Dermatologicals, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

  • Get a detailed picture of the Dermatologicals market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.

Table of Contents

KEY DATA FINDINGS
2024 DEVELOPMENTS
  • Minimal constant value growth in 2024
  • Competitive landscape remains diverse with players focusing on their own areas of expertise
  • Ageing population and climate change support growth
PROSPECTS AND OPPORTUNITIES
  • Branded dermatologicals set to prevail over generics due to perceived efficacy and format innovations
  • Canesten makes mark in vaginal antifungals
  • Multifunctionality of Bepanthen continues to support growth
CATEGORY DATA
  • Table 1 Sales of Dermatologicals by Category: Value 2019-2024
  • Table 2 Sales of Dermatologicals by Category: % Value Growth 2019-2024
  • Table 3 NBO Company Shares of Dermatologicals: % Value 2020-2024
  • Table 4 LBN Brand Shares of Dermatologicals: % Value 2021-2024
  • Table 5 LBN Brand Shares of Hair Loss Treatments: % Value 2021-2024
  • Table 6 Forecast Sales of Dermatologicals by Category: Value 2024-2029
  • Table 7 Forecast Sales of Dermatologicals by Category: % Value Growth 2024-2029
CONSUMER HEALTH IN POLAND
EXECUTIVE SUMMARY
  • Consumer health in 2024: The big picture
  • 2024 key trends
  • Competitive landscape
  • Retailing developments
  • What next for consumer health?
MARKET INDICATORS
  • Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2019-2024
  • Table 9 Life Expectancy at Birth 2019-2024
MARKET DATA
  • Table 10 Sales of Consumer Health by Category: Value 2019-2024
  • Table 11 Sales of Consumer Health by Category: % Value Growth 2019-2024
  • Table 12 NBO Company Shares of Consumer Health: % Value 2020-2024
  • Table 13 LBN Brand Shares of Consumer Health: % Value 2021-2024
  • Table 14 Penetration of Private Label in Consumer Health by Category: % Value 2019-2024
  • Table 15 Distribution of Consumer Health by Format: % Value 2019-2024
  • Table 16 Distribution of Consumer Health by Format and Category: % Value 2024
  • Table 17 Forecast Sales of Consumer Health by Category: Value 2024-2029
  • Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2024-2029
APPENDIX
  • OTC registration and classification
  • Vitamins and dietary supplements registration and classification
  • Self-medication/self-care and preventive medicine
  • Switches
DISCLAIMERDEFINITIONS
SOURCES
  • Summary 1 Research Sources